Genocea Biosciences (NASDAQ: GNCA) is one of 187 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its rivals? We will compare Genocea Biosciences to similar companies based on the strength of its institutional ownership, profitability, risk, valuation, analyst recommendations, dividends and earnings.
This is a summary of current ratings for Genocea Biosciences and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Genocea Biosciences Competitors||565||2470||6681||134||2.65|
Volatility and Risk
Genocea Biosciences has a beta of 1.94, suggesting that its stock price is 94% more volatile than the S&P 500. Comparatively, Genocea Biosciences’ rivals have a beta of 1.50, suggesting that their average stock price is 50% more volatile than the S&P 500.
This table compares Genocea Biosciences and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Genocea Biosciences Competitors||-4,607.57%||-480.30%||-43.17%|
Earnings and Valuation
This table compares Genocea Biosciences and its rivals gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Genocea Biosciences||$230,000.00||-$49.57 million||-0.52|
|Genocea Biosciences Competitors||$217.40 million||-$39.57 million||-16.79|
Genocea Biosciences’ rivals have higher revenue and earnings than Genocea Biosciences. Genocea Biosciences is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Insider & Institutional Ownership
34.7% of Genocea Biosciences shares are held by institutional investors. Comparatively, 48.1% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 6.7% of Genocea Biosciences shares are held by insiders. Comparatively, 14.5% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Genocea Biosciences rivals beat Genocea Biosciences on 8 of the 13 factors compared.
About Genocea Biosciences
Genocea Biosciences, Inc., is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company has one product candidate in Phase III clinical development, GEN-003, an immunotherapy for the treatment of genital herpes. It also has a pre-clinical immuno-oncology program focused on personalized cancer vaccines (GEN-009). The GEN-009 program leverages ATLAS to identify patient neoantigens, or newly formed antigens unique to each patient, that are associated with that individual’s tumor.
What are top analysts saying about Genocea Biosciences? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Genocea Biosciences and related companies.